Review Darunavir: pharmacokinetics and drug interactions
暂无分享,去创建一个
[1] A. Hill,et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. , 2007, British journal of clinical pharmacology.
[2] C. Katlama,et al. Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients: 24-Week Results of POWER 3 , 2007, Journal of acquired immune deficiency syndromes.
[3] M. Peeters,et al. Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers , 2007, Antiviral therapy.
[4] M. Peeters,et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers , 2007, Antiviral therapy.
[5] R. Haubrich,et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials , 2007, The Lancet.
[6] R. Hoetelmans,et al. The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV‐Negative Healthy Volunteers , 2007, Journal of clinical pharmacology.
[7] R. Haubrich,et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients , 2007, AIDS.
[8] L. Waters,et al. 8th International Congress on Drug Therapy in HIV Infection , 2007 .
[9] C. Katlama,et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 , 2007, AIDS.
[10] R. Bonomo,et al. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. , 2007, Future microbiology.
[11] R. Hoetelmans,et al. Pharmacokinetic Interaction between Darunavir Boosted with Ritonavir and Omeprazole or Ranitidine in Human Immunodeficiency Virus-Negative Healthy Volunteers , 2007, Antimicrobial Agents and Chemotherapy.
[12] R. Ebrahimi,et al. Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir , 2006, Journal of acquired immune deficiency syndromes.
[13] V. Sekar. Pharmacokinetic Interaction Between the HIV Protease Inhibitors TMC114 and Saquinavir, in the Presence of Low-Dose Ritonavir , 2006 .
[14] V. Sekar. Pharmacokinetic Interaction Between the Antiretroviral Agents TMC114 and Nevirapine, in the Presence of Low-Dose Ritonavir , 2006 .
[15] V. Sekar. Pharmacokinetic Interaction Between TMC114 and Ketoconazole, in the Absence and Presence of Low-Dose Ritonavir , 2006 .
[16] D. Back. Drug-drug interactions that matter. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[17] V. Calvez,et al. Salvage Therapy with Atazanavir/Ritonavir Combined to Tenofovir in HIV-Infected Patients with Multiple Treatment Failures: Randomized Anrs 107 Trial , 2006, Antiviral therapy.
[18] M. Boffito,et al. Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies , 2006, Journal of clinical pharmacology.
[19] R. Hoetelmans,et al. PI‐61 , 2006 .
[20] J. Montaner,et al. Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks , 2005, Journal of acquired immune deficiency syndromes.
[21] Dorothea C. Rudorf,et al. Drug-Drug Interactions and HIV Therapy: What Should Pharmacists Know? , 2005 .
[22] A. Winston,et al. The management of HIV-1 protease inhibitor pharmacokinetic interactions. , 2005, The Journal of antimicrobial chemotherapy.
[23] Dirk Jochmans,et al. TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[24] M. Kurowski,et al. Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy , 2005, Antiviral therapy.
[25] Celia A Schiffer,et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. , 2005, Journal of medicinal chemistry.
[26] J. Wangsa,et al. Effect of Multiple‐Dose Dexloxiglumide on the Pharmacokinetics of Oral Contraceptives in Healthy Women , 2005, Journal of clinical pharmacology.
[27] M. Kurowski,et al. The Steady-State Pharmacokinetics of Nelfinavir in Combination with Tenofovir in HIV-Infected Patients , 2005, Antiviral therapy.
[28] Celia A. Schiffer,et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor , 2004, Journal of Virology.
[29] S. Walmsley,et al. Polypharmacy in HIV: impact of data source and gender on reported drug utilization. , 2004, AIDS patient care and STDs.
[30] P. Anderson,et al. 6th International Workshop on Clinical Pharmacology of HIV Therapy , 2004, Expert opinion on pharmacotherapy.
[31] Irene T Weber,et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.
[32] M. Boffito,et al. Pharmacokinetic considerations for combining 2 protease inhibitors. , 2004, The AIDS reader.
[33] Irene T. Weber,et al. Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.
[34] E. Freire,et al. The binding of HIV-1 protease inhibitors to human serum proteins. , 2003, Biophysical chemistry.
[35] P. Jatlow,et al. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] T. Antoniou,et al. Interactions between Recreational Drugs and Antiretroviral Agents , 2002, The Annals of pharmacotherapy.
[37] A. Molla,et al. In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.
[38] J. Polli,et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[39] L. Highleyman. Protease inhibitors and sildenafil (Viagra) should not be combined. , 1999, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation.
[40] J. Kuper,et al. Drug Interactions of HIV Protease Inhibitors , 1999, Drug safety.
[41] A. T. Harvey,et al. Biochemical and clinical dose‐response curves with sertraline , 1996 .
[42] C. Bye,et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events , 1989, Acta psychiatrica Scandinavica. Supplementum.
[43] R. Hoetelmans,et al. Pharmacokinetics of Darunavir (TMC114) and Atazanavir during Coadministration in HIV-Negative, Healthy Volunteers , 2007, Drugs in R&D.
[44] Henry J. Kaiser,et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.